PHASE I STUDY OF ADOPTIVE T CELL THERAPY FOLLOWING HER2-PULSED DENDRITIC CELL VACCINE AND PEPINEMAB/TRASTUZUMAB IN PATIENTS WITH METASTATIC HER2-POSITIVE BREAST CANCER (MBC)

被引：0
|
作者：
Han, Hyo [1 ]
Evans, Elizabeth [2 ]
Fisher, Terrence [2 ]
Soliman, Hatem [1 ]
Khong, Hung [1 ]
Soyano, Aixa [1 ]
Costa, Ricardo [1 ]
Loftus, Loretta [1 ]
Lee, Kimberley [1 ]
Armaghani, Avan [1 ]
Liu, Hien [1 ]
Locke, Frederick [1 ]
Shrewsbury, Alexandria [1 ]
Malka, Jessica [1 ]
Karyampudi, Lavakumar [1 ]
Zauderer, Maurice [2 ]
Czerniecki, Brian [1 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[2] Vaccinex Inc, Rochester, NY USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2022年 / 10卷
关键词：
D O I：
10.1136/jitc-2022-SITC2022.0645
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
645
引用
收藏
页码：A676 / A676
页数：1
相关论文
共 50 条
  • [1] Phase I study of adoptive T cell therapy following HER2-pulsed dendritic cell vaccine and pepinemab/trastuzumab in patients with metastatic HER2-positive breast cancer (MBC)
    Han, Hyo S.
    Costa, Ricardo L.
    Soliman, Hatem Hussein
    Soyano, Aixa
    Khong, Hung T.
    Loftus, Loretta S.
    Lee, Kimberley T.
    Armaghani, Avan J.
    Liu, Hien
    Malka, Jessica
    Locke, Frederick L.
    Mo, Qianxing
    Whiting, Junmin
    Karyampudi, Lavakumar
    Evans, Elizabeth E.
    Fisher, Terrence Lee
    Zauderer, Maurice
    Czerniecki, Brian J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] Trastuzumab therapy in HER2-positive, metastatic breast cancer
    Smith, A. D.
    Guilbert, K.
    Lister, D.
    Streilein, S.
    Bourrier, V. C.
    Lozar, B.
    Navaratnam, S.
    Harding, G. A.
    Pitz, M. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [3] Outcome of HER2-Positive (HER2+) Metastatic Breast Cancer Patients (MBC) Treated with Trastuzumab (T): An Institutional Based Review
    Guilhaume, M-N
    Dieras, V
    Fall, M.
    Pierga, J-Y
    Beuzeboc, P.
    Cottu, P. H.
    Simondi, C.
    Courbard, M.
    Mignot, L.
    Livartowski, A.
    CANCER RESEARCH, 2009, 69 (24) : 801S - 801S
  • [4] Lapatinib with trastuzumab for heavily treated HER2-positive metastatic breast cancer (mBC).
    Sotelo, Miguel J.
    Manso, Luis
    Garcia Saenz, Jose Angel
    Ciruelos, Eva M.
    Moreno, Fernando
    Mendiola, Cesar
    Callata, Hector
    Ghanem, Ismael
    Cabezas, Santiago
    Gonzalez-Larriba, Jose-Luis
    Diaz Rubio, Eduardo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [5] Phase I and pharmacokinetic study of trastuzumab emtansine in Japanese patients with HER2-positive metastatic breast cancer
    Yamamoto, Harukaze
    Ando, Masashi
    Aogi, Kenjiro
    Iwata, Hiroji
    Tamura, Kenji
    Yonemori, Kan
    Shimizu, Chikako
    Hara, Fumikata
    Takabatake, Daisuke
    Hattori, Masaya
    Asakawa, Takashi
    Fujiwara, Yasuhiro
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2015, 45 (01) : 12 - 18
  • [6] TRASTUZUMAB-BASED THERAPY AFTER DISEASE PROGRESSION FOLLOWING LAPATINIB AND CAPECITABINE IN HER2-POSITIVE (HER2+) METASTATIC BREAST CANCER (MBC)
    Metro, G.
    Fabi, A.
    Foglietta, J.
    Russillo, M.
    Stocchi, L.
    Crino, L.
    Papaldo, P.
    Sperduti, I.
    Cognetti, F.
    Gori, S.
    ANNALS OF ONCOLOGY, 2010, 21 : 100 - 101
  • [7] Study of lapatinib (T) in combination with trastuzumab (T) in women heavily pretreated with HER2-positive metastatic breast cancer (MBC).
    Salvador, Javier
    Ruiz Borrego, Manuel
    Valero, Maria
    Bayo, Juan L.
    De La Cruz-Merino, Luis
    Carabantes, FRancisco
    Rodriguez de la Borbolla, Maria
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [8] A phase II study of ixabepilone and trastuzumab for metastatic HER2-positive breast cancer
    Tolaney, S. M.
    Najita, J.
    Sperinde, J.
    Huang, W.
    Chen, W. Y.
    Savoie, J.
    Fornier, M.
    Winer, E. P.
    Bunnell, C.
    Krop, I. E.
    ANNALS OF ONCOLOGY, 2013, 24 (07) : 1841 - 1847
  • [9] Retreatment with trastuzumab (T)-based therapy in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC) resistant to lapatinib (L)-based therapy.
    Gori, S.
    Montemurro, F.
    Spazzapan, S.
    Metro, G.
    Foglietta, J.
    Bisagni, G.
    Ferzi, A.
    Silva, R. R.
    Gamucci, T.
    Clavarezza, M.
    Stocchi, L.
    Fabi, A.
    Cognetti, F.
    Torrisi, E.
    Crivellari, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [10] Trastuzumab emtansine in HER2-positive metastatic breast cancer
    Montemurro, Filippo
    LANCET ONCOLOGY, 2017, 18 (06): : 696 - 697
12345